MYCOPHENOLATE MOFETIL

Post-LOE

mycophenolate mofetil

ANDAORALTABLET
Approved
Oct 2008
Lifecycle
Post-LOE
Competitive Pressure
60/100
Clinical Trials
20

Mechanism of Action

(MMF) is absorbed following oral administration and hydrolyzed to mycophenolic acid (MPA), the active metabolite. MPA is a selective uncompetitive inhibitor of the two isoforms (type I and type II) of inosine monophosphate dehydrogenase (IMPDH) leading to inhibition of the de novo pathway of…

Clinical Trials (5)

NCT06615050Phase 3Recruiting

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

Started Apr 2025
572 enrolled
Graft-versus-host Disease (GVHD)
NCT05538208Phase 2Recruiting

The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

Started Jun 2024
105 enrolled
Lupus Nephritis
NCT06114953Phase 4Unknown

Comparative Efficacy of Mizoribine With Mycophenolate Mofetil for Living Related Kidney Transplantation Recipients

Started Jan 2023
152 enrolled
Kidney Transplant Immunosuppression
NCT04039373Phase 1Completed

Effects of BMS-986256 at Steady State on the Single Dose Pharmacokinetics of Mycophenolate Mofetil

Started Jul 2019
15 enrolled
Healthy Participants
NCT03899103Phase 3Completed

Compare Efficacy and Safety of Repeated Courses of Rituximab to That of Maintenance Mycophenolate Mofetil Following Single Course of Rituximab Among Children With Steroid Dependent Nephrotic Syndrome

Started May 2019
100 enrolled
Steroid-Dependent Nephrotic Syndrome